Parabilis Medicines Inc opened trading at $33.35 per share, representing a 67% increase over its initial public offering price of $20.00 per share. After the initial session, the stock trimmed gains and was trading at $29.50, which remains 47.5% higher than the IPO price.
The clinical-stage biopharmaceutical firm had priced an upsized IPO that offers 33,500,000 shares of common stock. As part of the financing structure, Parabilis granted the offering underwriters a 30-day option to buy an additional 5,025,000 shares at the IPO price, subject to deductions for underwriting discounts and commissions.
The company anticipates the offering will close on or about June 11, 2026, contingent on customary closing conditions. Before accounting for underwriting discounts, commissions and offering expenses, Parabilis expects to receive gross proceeds of $670 million from the IPO.
In a related transaction, Parabilis agreed to sell 4,166,666 shares to Regeneron Pharmaceuticals Inc. at $18.00 per share in a concurrent private placement. That private placement is expected to generate approximately $75 million in proceeds.
Institutional firms serving as active book-running managers for the offering include Leerink Partners, BofA Securities, Evercore ISI and Guggenheim Securities. LifeSci Capital LLC is listed as a passive bookrunning manager for the transaction.
Parabilis describes its scientific approach as focused on creating medicines that target proteins historically regarded as undruggable drivers of human disease. The company uses a proprietary technology called the Helicons platform, which engineers stabilized helical peptides designed to bind to and modulate proteins that conventional drugs cannot reach.
This report summarizes the initial market reaction to Parabilis Medicines' public debut and outlines the financing details disclosed by the company. The information presented reflects the terms and expectations as announced, including offering size, underwriter arrangements, expected proceeds and the concurrent private placement with Regeneron.